Comparative Pharmacology
Head-to-head clinical analysis: POLYMOX versus TOTACILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYMOX versus TOTACILLIN.
POLYMOX vs TOTACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
Bactericidal: inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation. Active against gram-positive bacteria and some gram-negative bacteria.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; maximum 4 g/day.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life = 1-1.5 hours in adults; prolonged in renal impairment (up to 12-20 hours in anuria)
Terminal elimination half-life: 1.0-1.5 hours in normal renal function. Extended to 2-6 hours in renal impairment; requires dose adjustment when CrCl <30 mL/min.
Renal (70-80% unchanged via tubular secretion and glomerular filtration); biliary/fecal (small amount, <5%)
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5% as unchanged drug and metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic